Overview

Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Status:
Recruiting
Trial end date:
2036-01-20
Target enrollment:
Participant gender:
Summary
This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients: - Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments. - Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic treatments.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Institut Curie
Collaborator:
Fondation Rothschild Paris
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Melphalan
Topotecan
Vincristine